Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Synthon Biopharmaceuticals prepares for phase I study of SYD-985

Jan. 16, 2014

Merck & Co. begins rolling submission of BLA for MK-3475

Jan. 14, 2014

Monoclonal antibody Hu3F8 receives FDA orphan drug status for osteosarcoma

Jan. 14, 2014

EMA accepts Biovest's MAA for BiovaxID

Jan. 14, 2014

GlaxoSmithKline presents a novel antibody-drug conjugate for the treatment of multiple myeloma

Jan. 13, 2014

Researchers present phase I results for 225Ac-lintuzumab in older patients with AML

Jan. 13, 2014

IGN-532 shows preclinical efficacy in xenograft models of AML

Jan. 10, 2014

Galena enrolls first patient in phase II trial of GALE-301 cancer immunotherapy in ovarian cancer

Jan. 9, 2014

Development of a novel ROR1 peptide-based cancer vaccine

Jan. 9, 2014

Committee recommends stopping Imbruvica study based on significant survival improvement

Jan. 8, 2014

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...